These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 31753019)

  • 21. B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cells.
    Hurchla MA; Sedy JR; Gavrieli M; Drake CG; Murphy TL; Murphy KM
    J Immunol; 2005 Mar; 174(6):3377-85. PubMed ID: 15749870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Allergen-specific immunotherapy alters the expression of B and T lymphocyte attenuator, a co-inhibitory molecule, in allergic rhinitis.
    Okano M; Otsuki N; Azuma M; Fujiwara T; Kariya S; Sugata Y; Higaki T; Kino K; Tanimoto Y; Okubo K; Nishizaki K
    Clin Exp Allergy; 2008 Dec; 38(12):1891-900. PubMed ID: 19016801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Exploration of the mechanism of xinfeng capsule in the treatment of ankylosing spondylitis based on B and T lymphocyte attenuator and oxidative stress].
    Qi YJ; Liu J; Zheng L; Cao YX; Wan L
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Jan; 35(1):25-32. PubMed ID: 25790670
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B and T Lymphocyte Attenuator is a Target of miR-155 during Naïve CD4+ T Cell Activation.
    Liu Y; Nie W; Jin Y; Zhuo A; Zang Y; Xiu Q
    Iran J Immunol; 2016 Jun; 13(2):89-99. PubMed ID: 27350630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway.
    Rodriguez-Barbosa JI; Fernandez-Renedo C; Moral AMB; Bühler L; Del Rio ML
    Cell Mol Immunol; 2017 Jun; 14(6):497-510. PubMed ID: 26924526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of B and T lymphocyte attenuator, retinoid-related orphan receptor gamma-isoform-t and interleukin 7 in psoriasis vulgaris.
    Youssef RM; El-Ramly AZ; Hussien MF; Shoukry NM; Amr K
    Australas J Dermatol; 2019 May; 60(2):e132-e137. PubMed ID: 30671936
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells.
    Thibult ML; Rivals JP; Mamessier E; Gertner-Dardenne J; Pastor S; Speiser DE; Derré L; Olive D
    J Mol Med (Berl); 2013 Feb; 91(2):195-205. PubMed ID: 22903545
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation.
    Hobo W; Norde WJ; Schaap N; Fredrix H; Maas F; Schellens K; Falkenburg JH; Korman AJ; Olive D; van der Voort R; Dolstra H
    J Immunol; 2012 Jul; 189(1):39-49. PubMed ID: 22634623
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD19
    Jiang Q; Fu Q; Chang Y; Liu Z; Zhang J; Xu L; Zhu Y; Wang Y; Zhang W; Xu J
    Cancer Immunol Immunother; 2019 Jan; 68(1):45-56. PubMed ID: 30259082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical Trials of Novel Targeted Therapies in Ovarian Cancer: Moving Beyond Poly ADP Ribose Polymerase (PARP) Inhibitors.
    Guo Q; Yang Q; Li J; Liu G; Nikoulin I; Jia S
    Curr Pharm Biotechnol; 2018; 19(14):1114-1121. PubMed ID: 30585545
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Significance of Increased Expression of Annexin A10 (ANXA10) in Serous Epithelial Ovarian Cancer.
    Wang J; Zhao S; Wang F; Wang J; Zhang Y
    Med Sci Monit; 2019 Jul; 25():5666-5673. PubMed ID: 31363077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and function of the B and T lymphocyte attenuator (BTLA/CD272) on human T cells.
    Otsuki N; Kamimura Y; Hashiguchi M; Azuma M
    Biochem Biophys Res Commun; 2006 Jun; 344(4):1121-7. PubMed ID: 16643847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.
    Staley SA; Tucker K; Newton M; Ertel M; Oldan J; Doherty I; West L; Zhang Y; Gehrig PA
    Gynecol Oncol; 2020 Mar; 156(3):695-700. PubMed ID: 31928805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin‑33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis.
    Sekiya A; Suzuki S; Tanaka A; Hattori S; Shimizu Y; Yoshikawa N; Koya Y; Kajiyama H; Kikkawa F
    Int J Oncol; 2019 Sep; 55(3):755-765. PubMed ID: 31322193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ligation of B and T lymphocyte attenuator prevents the genesis of experimental cerebral malaria.
    Lepenies B; Pfeffer K; Hurchla MA; Murphy TL; Murphy KM; Oetzel J; Fleischer B; Jacobs T
    J Immunol; 2007 Sep; 179(6):4093-100. PubMed ID: 17785848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased B and T lymphocyte attenuator in Behcet's disease may trigger abnormal Th17 and Th1 immune responses.
    Ye Z; Deng B; Wang C; Zhang D; Kijlstra A; Yang P
    Sci Rep; 2016 Feb; 6():20401. PubMed ID: 26841832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function.
    Serriari NE; Gondois-Rey F; Guillaume Y; Remmerswaal EB; Pastor S; Messal N; Truneh A; Hirsch I; van Lier RA; Olive D
    J Immunol; 2010 Sep; 185(6):3140-8. PubMed ID: 20693422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia.
    Sordo-Bahamonde C; Lorenzo-Herrero S; Martínez-Pérez A; Gonzalez-Rodriguez AP; Payer ÁR; González-García E; Aguilar-García C; González-Rodríguez S; López-Soto A; García-Torre A; Gonzalez S
    Cancer Immunol Immunother; 2023 Jul; 72(7):2529-2539. PubMed ID: 37041226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
    Gagno S; Poletto E; Bartoletti M; Quartuccio L; Romualdi C; Garziera M; Scalone S; Sorio R; Dreussi E; Zanusso C; De Mattia E; Roncato R; Cecchin E; Giorda G; De Vita S; Dal Bo M; Puglisi F; Toffoli G
    Gynecol Oncol; 2020 Jan; 156(1):233-242. PubMed ID: 31711657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
    McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
    BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.